Tarsus Pharmaceuticals' General Counsel Bryan Wahl Sells Shares to Cover Tax Obligations: Analysis and Financial Performance Review
Tarsus Pharmaceuticals' General Counsel, Bryan Wahl, recently sold 12,440 shares of common stock in three separate transactions between March 17 and March 19, 2026, totaling approximately $850,417. The sales were made at prices ranging from $67.0 to $69.42 per share, with the stock currently trading at $66.75. Despite a year-to-date decline of 18%, the shares have seen a 35% increase over the past year.
On March 17, Wahl sold 4,084 shares at $69.42 per share, followed by another sale of 4,125 shares at $68.71 per share on March 18. The final transaction took place on March 19, with 4,231 shares sold at $67.0 per share. After these sales, Wahl retains ownership of 63,959 shares of Tarsus Pharmaceuticals.
The sales were made to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units, as mandated by Tarsus Pharmaceuticals. They do not reflect any discretionary decision by Wahl. Tarsus Pharmaceuticals is considered undervalued by InvestingPro analysis, with a strong financial position and a positive Financial Health Score. A detailed Pro Research Report is available for further analysis.
Tarsus Pharmaceuticals Inc. recently reported robust financial results for the fourth quarter of 2025, with net product sales reaching $151.7 million for the quarter and $451.4 million for the full year. The company's flagship product, XDEMVY, drove this significant revenue growth. Despite the positive performance, the stock experienced a slight decline in aftermarket trading, reflecting mixed investor sentiment. These developments underscore Tarsus Pharmaceuticals' financial progress and market position.
ProPicks AI evaluates TARS and other companies monthly using over 100 financial metrics to identify promising stock opportunities based on fundamentals, momentum, and valuation. The AI has a track record of identifying successful stocks like Super Micro Computer (+185%) and AppLovin (+157%). To explore if TARS is featured in any ProPicks AI strategies or discover better opportunities in the same sector, visit the platform for more information.